6730.TWO Lagis Enterprise Co., Ltd.
- Market cap
- TWD 1.17B
- P/E
- 16.3x
- P/B
- 1.59x
- ROE
- 8.7%
- Dividend yield
- 2.74%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6730.TWO undervalued?
Graham number6730.TWO trades 7.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lagis Enterprise Co., Ltd. fundamental analysis
No fundamental analysis for Lagis Enterprise Co., Ltd. yet.
Lagis Enterprise Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lagis Enterprise Co., Ltd.
Lagis Enterprise Co., Ltd. engages in the manufacturing, processing, and sale of surgical instruments, equipment, and related medical devices Taiwan and China. Its products include trocars, include optical tip trocar, dilating tip trocar, shielded bladed tip trocar, blunt tip trocar, TRE trocar system, balloon trocar; single port surgery devices, include advanced single port device, single port kit for TAMIS, and advanced single port device for vNOTES; path cap and shield wo…
Full company profileLagis Enterprise Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lagis Enterprise Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 407M | 319M | 393M | 442M | 460M | 454M | 488M | 484M |
| Gross Profit | 217M | 139M | 178M | 223M | 219M | 221M | 236M | 219M |
| Operating Income | 112M | 40.5M | 61.3M | 88.8M | 77.1M | 81.2M | 87.9M | 77.0M |
| EBITDA | 137M | 67.8M | 92.3M | 121M | 112M | 117M | 132M | 140M |
| Net Income | 89.2M | 32.3M | 48.9M | 71.0M | 64.1M | 68.2M | 69.3M | 64.3M |
| EPS | 2.84 | 1.01 | 1.52 | 2.18 | 1.98 | 2.13 | 1.91 | 1.77 |
| Balance Sheet | ||||||||
| Total Assets | 587M | 538M | 594M | 659M | 845M | 1.09B | 1.14B | 1.17B |
| Total Liabilities | 102M | 66.2M | 98.9M | 124M | 305M | 506M | 377M | 427M |
| Shareholders' Equity | 485M | 472M | 495M | 534M | 541M | 580M | 762M | 740M |
| Cash & Short-term Investments | 151M | 115M | 151M | 129M | 89.9M | 69.2M | 95.3M | 114M |
| Total Debt | 3.99M | 2.80M | 10.1M | 9.03M | 178M | 394M | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 110M | 29.8M | 96.2M | 84.3M | 77.5M | 74.1M | 132M | 89.3M |
| Capital Expenditure | 10.5M | 17.4M | 29.5M | 69.9M | 226M | 276M | 92.0M | 38.8M |
| Free Cash Flow | 99.3M | 12.4M | 66.7M | 14.3M | -149M | -202M | 39.6M | 50.5M |
| Ratios | ||||||||
| ROE | 18.4% | 6.8% | 9.9% | 13.3% | 11.9% | 11.8% | 9.1% | 8.7% |
| ROA | 15.2% | 6.0% | 8.2% | 10.8% | 7.6% | 6.3% | 6.1% | 5.5% |
| Net Profit Margin | 21.9% | 10.1% | 12.5% | 16.1% | 13.9% | 15.0% | 14.2% | 13.3% |
| Debt to Equity | 0.01x | 0.01x | 0.02x | 0.02x | 0.33x | 0.68x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lagis Enterprise Co., Ltd. dividends
- Dividend yield
- 2.74%
- Forward dividend
- 1.50 TWD
- Payout ratio
- 46.3%
- Ex-dividend date
- Jul 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 32.1M | 0.88 | 46.3% |
| 2024 | TWD 32.0M | 1.00 | 46.9% |
| 2023 | TWD 57.6M | 1.78 | 89.9% |
| 2022 | TWD 32.0M | 0.98 | 45.0% |
| 2021 | TWD 25.6M | 0.79 | 52.3% |
| 2020 | 45.7M | 1.42 | 141.4% |
| 2019 | 50.5M | 1.61 | 56.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1050:1000 on Aug 26, 2020.
Who owns Lagis Enterprise Co., Ltd.
- Insiders 56.99%
- Institutions 0.00%
- Public & others 43.01%
- Shares outstanding 36.3M
- Free float 16.9M
Lagis Enterprise Co., Ltd. company profile
- Company name
- Lagis Enterprise Co., Ltd.
- Ticker
- 6730.TWO
- ISIN
- TW0006730005
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Fiscal year end
- December
- Address
- No.29, Gong 1st Road, Taichung, Taiwan, 437101
- Phone
- 886 4 2682 0790
- Website
- lagis.com.tw
About Lagis Enterprise Co., Ltd.
Lagis Enterprise Co., Ltd. engages in the manufacturing, processing, and sale of surgical instruments, equipment, and related medical devices Taiwan and China. Its products include trocars, include optical tip trocar, dilating tip trocar, shielded bladed tip trocar, blunt tip trocar, TRE trocar system, balloon trocar; single port surgery devices, include advanced single port device, single port kit for TAMIS, and advanced single port device for vNOTES; path cap and shield wound reactors; energy bipolar forceps; suction irrigation systems and irrigation pumps; electrosurgery system; endo endoscopic instruments, include scissors and dissectors, graspers, mini laparoscopy grasping device, and laparoscopic electrode; and retrieval specimen bags. The company sells its products under LAGIS brand name. Lagis Enterprise Co., Ltd. was founded in 2004 and is headquartered in Taichung, Taiwan.
Lagis Enterprise Co., Ltd. management
3- Mr. Zhenghong ChenRepresentative Chairman, CEO and Head of R&D and Sales Departments
- Mr. Wenguo QiuManagement Manager, Head of Finance, Head of Corporate Governance Accounting Supervisor
- Mr. Zhengxiong ChenGM & Representative Director